About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Prices $31,000,000,000 Debt Offering
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Proposed Notes Offering
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Reports First-Quarter 2023 Results
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Declares Second-Quarter 2023 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
From Pfizer Inc.
Via Business Wire
Tickers PFE
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.